SAGE Therapeutics (SAGE) Misses Q3 EPS by 9c

SAGE Therapeutics (NASDAQ: SAGE) reported Q3 EPS of ($2.31), $0.09 worse than the analyst estimate of ($2.22). Revenue for the quarter came in at $1.74 million versus the consensus estimate of $1.68 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

You May Also Be Interested In

• Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
• Academy Sports surges on earnings beat and raised guidance
• Core & Main, Inc (CNM) Tops Q3 EPS by 2c ; Offers Guidance